IL310801A - Acetyl-leucine for use in treating neurodegenerative diseases - Google Patents

Acetyl-leucine for use in treating neurodegenerative diseases

Info

Publication number
IL310801A
IL310801A IL310801A IL31080124A IL310801A IL 310801 A IL310801 A IL 310801A IL 310801 A IL310801 A IL 310801A IL 31080124 A IL31080124 A IL 31080124A IL 310801 A IL310801 A IL 310801A
Authority
IL
Israel
Prior art keywords
leucine
acetyl
disease
parkinson
use according
Prior art date
Application number
IL310801A
Other languages
English (en)
Hebrew (he)
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59859424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL310801(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1613829.9A external-priority patent/GB201613829D0/en
Priority claimed from GBGB1702551.1A external-priority patent/GB201702551D0/en
Priority claimed from GBGB1705766.2A external-priority patent/GB201705766D0/en
Priority claimed from GBGB1706867.7A external-priority patent/GB201706867D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of IL310801A publication Critical patent/IL310801A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL310801A 2016-08-11 2017-08-11 Acetyl-leucine for use in treating neurodegenerative diseases IL310801A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1613829.9A GB201613829D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1702551.1A GB201702551D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1705766.2A GB201705766D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1706867.7A GB201706867D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
PCT/IB2017/054929 WO2018029658A1 (en) 2016-08-11 2017-08-11 Therapeutic agents for neurodegenerative diseases

Publications (1)

Publication Number Publication Date
IL310801A true IL310801A (en) 2024-04-01

Family

ID=59859424

Family Applications (3)

Application Number Title Priority Date Filing Date
IL310801A IL310801A (en) 2016-08-11 2017-08-11 Acetyl-leucine for use in treating neurodegenerative diseases
IL264641A IL264641B2 (en) 2016-08-11 2017-08-11 Acetyl-leucine for use in treating neurodegenerative diseases
IL310799A IL310799A (en) 2016-08-11 2017-08-11 Acetyl-leucine for use in treating neurodegenerative diseases

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL264641A IL264641B2 (en) 2016-08-11 2017-08-11 Acetyl-leucine for use in treating neurodegenerative diseases
IL310799A IL310799A (en) 2016-08-11 2017-08-11 Acetyl-leucine for use in treating neurodegenerative diseases

Country Status (28)

Country Link
US (3) US12144792B2 (enExample)
EP (3) EP3583940A1 (enExample)
JP (3) JP6957602B2 (enExample)
KR (4) KR102785448B1 (enExample)
CN (4) CN109789114A (enExample)
AU (3) AU2017308865B2 (enExample)
BR (1) BR112019002730A2 (enExample)
CA (1) CA3033564A1 (enExample)
CY (1) CY1121930T1 (enExample)
DK (1) DK3416631T3 (enExample)
ES (1) ES2733677T3 (enExample)
HR (1) HRP20191055T1 (enExample)
HU (1) HUE045043T2 (enExample)
IL (3) IL310801A (enExample)
LT (1) LT3416631T (enExample)
MA (2) MA47521A (enExample)
MD (1) MD3416631T2 (enExample)
ME (1) ME03454B (enExample)
MX (3) MX383499B (enExample)
PL (1) PL3416631T3 (enExample)
PT (1) PT3416631T (enExample)
RS (1) RS59048B1 (enExample)
RU (1) RU2756519C2 (enExample)
SG (1) SG11201901063SA (enExample)
SI (1) SI3416631T1 (enExample)
SM (1) SMT201900370T1 (enExample)
TN (1) TN2019000033A1 (enExample)
WO (1) WO2018029658A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10219815B2 (en) 2005-09-22 2019-03-05 The Regents Of The University Of Michigan Histotripsy for thrombolysis
JP6979882B2 (ja) 2015-06-24 2021-12-15 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン 脳組織の治療のための組織破砕療法システムおよび方法
MD3359146T2 (ro) 2016-08-11 2019-04-30 Intrabio Ltd Compoziții farmaceutice și utilizări direcționate spre bolile de depozitare lizozomală
CN109789114A (zh) 2016-08-11 2019-05-21 内在生物技术有限公司 神经退行性疾病的治疗剂
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
CA3079194A1 (en) * 2017-10-18 2019-04-25 Intrabio Limited Therapeutic agents for neurodegenerative diseases
LT3752141T (lt) * 2018-02-15 2024-07-10 Intrabio Ltd Acetil-leucinas, skirtas panaudoti gydant neramių kojų sindromą
US11813484B2 (en) 2018-11-28 2023-11-14 Histosonics, Inc. Histotripsy systems and methods
WO2020115715A1 (en) * 2018-12-06 2020-06-11 Intrabio Ltd. Deuterated analogs of acetyl-leucine
RS65849B1 (sr) * 2019-03-02 2024-09-30 Intrabio Ltd (n-)acetil-l-leucin za upotrebu u lečenju traumatske povrede mozga
WO2021055443A1 (en) * 2019-09-17 2021-03-25 Hoffmann-La Roche Inc. Improvements in personalized healthcare for patients with movement disorders
US20230051742A1 (en) * 2020-01-13 2023-02-16 Intrabio Ltd. Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
CA3179105A1 (en) * 2020-05-22 2021-11-25 Michael Strupp The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease
KR20250102047A (ko) 2022-10-28 2025-07-04 히스토소닉스, 인크. 히스토트립시 시스템들 및 방법들
AU2024257180A1 (en) 2023-04-20 2025-09-18 Histosonics, Inc. Histotripsy systems and associated methods including user interfaces and workflows for treatment planning and therapy
WO2025151578A1 (en) * 2024-01-12 2025-07-17 Intrabio Inc. N-acetyl-leucine for use in the treatment of prodromal alpha-synucleinopathies
WO2025163129A1 (en) * 2024-02-01 2025-08-07 Intrabio Ltd. Acetyl-leucine for treating parkinson´s disease
WO2025166100A1 (en) 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders
WO2025175092A1 (en) * 2024-02-14 2025-08-21 Intrabio Inc. Acetyl leucine for treating syngap1-related disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
WO2008101693A2 (en) 2007-02-22 2008-08-28 Beiersdorf Ag Cosmetic and pharmaceutical applications of n-acylated amino acids and structurally related compounds
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
WO2015065891A1 (en) * 2013-10-28 2015-05-07 Naurex, Inc. Nmda receptor modulators and prodrugs, salts, and uses thereof
LT3445351T (lt) 2016-04-19 2024-11-25 Intrabio Ltd Acetil-leucinas arba farmaciniu požiūriu priimtina jo druska, skirti judrumo pagerinimui
CN109789114A (zh) 2016-08-11 2019-05-21 内在生物技术有限公司 神经退行性疾病的治疗剂

Also Published As

Publication number Publication date
AU2025202077A1 (en) 2025-04-10
CY1121930T1 (el) 2020-10-14
KR102413756B1 (ko) 2022-06-27
US12144792B2 (en) 2024-11-19
MA43828A (fr) 2018-12-26
WO2018029658A1 (en) 2018-02-15
RU2021128045A (ru) 2021-11-16
PT3416631T (pt) 2019-07-11
SI3416631T1 (sl) 2019-09-30
AU2023202121A1 (en) 2023-05-04
BR112019002730A2 (pt) 2019-05-14
CA3033564A1 (en) 2018-02-15
MX383499B (es) 2025-03-14
KR102785448B1 (ko) 2025-03-21
MD3416631T2 (ro) 2019-09-30
EP3416631A1 (en) 2018-12-26
ME03454B (me) 2020-01-20
RU2019106506A (ru) 2020-09-17
HUE045043T2 (hu) 2019-12-30
US20240189267A1 (en) 2024-06-13
TN2019000033A1 (fr) 2020-07-15
MX2019001575A (es) 2019-08-01
IL310799A (en) 2024-04-01
IL264641A (en) 2019-04-30
CN116492328A (zh) 2023-07-28
RU2019106506A3 (enExample) 2020-10-29
KR20240068761A (ko) 2024-05-17
IL264641B2 (en) 2024-07-01
MA47521A (fr) 2021-04-21
KR20250042197A (ko) 2025-03-26
HRP20191055T1 (hr) 2019-09-06
IL264641B1 (en) 2024-03-01
JP2019524822A (ja) 2019-09-05
AU2017308865A1 (en) 2019-02-21
EP3416631B1 (en) 2019-05-15
EP3583940A1 (en) 2019-12-25
EP4467195A2 (en) 2024-11-27
AU2017308865B2 (en) 2023-04-13
SG11201901063SA (en) 2019-03-28
MX2021006901A (es) 2021-07-07
AU2023202121B2 (en) 2025-01-23
KR20190039227A (ko) 2019-04-10
LT3416631T (lt) 2019-08-26
CN121081445A (zh) 2025-12-09
US20230210799A1 (en) 2023-07-06
CN109789114A (zh) 2019-05-21
RS59048B1 (sr) 2019-08-30
JP2023175762A (ja) 2023-12-12
DK3416631T3 (da) 2019-07-15
RU2756519C2 (ru) 2021-10-01
MA43828B1 (fr) 2019-09-30
JP2022003085A (ja) 2022-01-11
JP6957602B2 (ja) 2021-11-02
EP4467195A3 (en) 2025-03-19
KR20220093385A (ko) 2022-07-05
PL3416631T3 (pl) 2019-11-29
SMT201900370T1 (it) 2019-09-09
US20200179320A1 (en) 2020-06-11
CN116459244A (zh) 2023-07-21
MX2024004439A (es) 2025-11-03
ES2733677T3 (es) 2019-12-02

Similar Documents

Publication Publication Date Title
IL310801A (en) Acetyl-leucine for use in treating neurodegenerative diseases
Ginovart et al. Binding characteristics and sensitivity to endogenous dopamine of [11C]‐(+)‐PHNO, a new agonist radiotracer for imaging the high‐affinity state of D2 receptors in vivo using positron emission tomography
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
EP1992965A3 (de) Verfahren zur Kalibrierung eines Positronen-Emissions-Tomographen einer Strahlentherapievorrichtung sowie Strahlentherapievorrichtung
FI3287124T3 (fi) Ketamiinin oraalinen annosmuoto
EP4076422A1 (en) Methods for improving neurological diseases and disorders
ECSP20011578A (es) Composiciones de aminoácidos para el tratamiento de enfermedad hepática
Rominger et al. Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: A [123I] β-CIT SPECT study
JP2013522326A5 (enExample)
FI3347002T3 (fi) Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa
MX2023001671A (es) Procedimiento y compuesto para su uso en el tratamiento y/o prevención de la netosis.
JP2019529514A5 (enExample)
RU2016132762A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
MX2020007487A (es) Composiciones de diagnostico para produccion de imagenes de tomografia por emision de positrones, metodo para fabricar la composicion de diagnostico y su uso en diagnostico.
BR112014031649A2 (pt) composto representado pela fórmula 1 tendo a enzima inibidora de atividade 11b-hsd1; método para sua produção e composição farmacêutica contendo o mesmo como ingrediente ativo
JP2020510073A5 (enExample)
IL273929B1 (en) Therapeutic agents for neurodegenerative diseases
JP2015512948A5 (enExample)
BR112013006519A2 (pt) composto, composição farmacêutica, métodos de fabricar um composto, de formar imagem e de detectar tecido neoplástico in vivo, e, cassete
EP3972432A4 (en) Pharmaceutical formulations and methods for delivering a therapeutic, diagnostic, or imaging agent to cd206
JP2014530847A5 (enExample)
JP2019513151A5 (enExample)
EP3848039A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING FABRY'S DISEASE, CONTAINING A TSP1 PROTEIN INHIBITOR AS ACTIVE INGREDIENT
Gupta et al. Onychomycosis
WO2009036768A3 (en) Diagnosing potential weight gain in a subject